JP2017500562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500562A5 JP2017500562A5 JP2016538603A JP2016538603A JP2017500562A5 JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5 JP 2016538603 A JP2016538603 A JP 2016538603A JP 2016538603 A JP2016538603 A JP 2016538603A JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- sample
- subject
- kit
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322094.2A GB201322094D0 (en) | 2013-12-13 | 2013-12-13 | Methods and compositions relating to alzheimers disease |
| GB1322094.2 | 2013-12-13 | ||
| PCT/GB2014/053692 WO2015087087A1 (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500562A JP2017500562A (ja) | 2017-01-05 |
| JP2017500562A5 true JP2017500562A5 (enExample) | 2018-01-25 |
| JP6803230B2 JP6803230B2 (ja) | 2020-12-23 |
Family
ID=50030903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538603A Active JP6803230B2 (ja) | 2013-12-13 | 2014-12-12 | アルツハイマー病に関するバイオマーカー及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12345717B2 (enExample) |
| EP (1) | EP3080609B1 (enExample) |
| JP (1) | JP6803230B2 (enExample) |
| CA (1) | CA2933398C (enExample) |
| GB (1) | GB201322094D0 (enExample) |
| WO (1) | WO2015087087A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| CN109791139A (zh) * | 2016-08-09 | 2019-05-21 | 大塚制药株式会社 | 使用尿液生物标记的阿兹海默氏症的辅助诊断方法 |
| CN110603550A (zh) * | 2016-12-13 | 2019-12-20 | 阿克利互动实验室公司 | 利用导航任务识别生物标志物和利用导航任务进行治疗的平台 |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| AU2018359624A1 (en) * | 2017-10-31 | 2020-04-30 | Ge Healthcare Limited | Medical system for diagnosing cognitive disease pathology and/or outcome |
| GB201814807D0 (en) * | 2018-09-12 | 2018-10-24 | Univ Newcastle | Dementia Biomarkers |
| SG11202106410VA (en) * | 2019-01-09 | 2021-07-29 | Univ Washington | Multiplexed assay and methods of use thereof |
| US11860170B2 (en) * | 2019-05-16 | 2024-01-02 | Procisedx Inc. | Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood |
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| EP4051812A1 (en) * | 2019-10-28 | 2022-09-07 | AgenT | Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease |
| KR20230004597A (ko) * | 2020-04-14 | 2023-01-06 | 주식회사 지뉴브 | 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물 |
| EP4237857A1 (en) * | 2020-10-30 | 2023-09-06 | Baseline Global, Inc. | Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease |
| US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
| CN115066615A (zh) * | 2020-12-28 | 2022-09-16 | 株式会社Mcbi | 判定辅助信息生成方法、判定辅助信息生成系统以及信息处理装置 |
| WO2022192019A1 (en) * | 2021-03-08 | 2022-09-15 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CN115612728A (zh) * | 2021-07-16 | 2023-01-17 | 深圳先进技术研究院 | 一种神经退行性疾病标志物及其应用 |
| CN114705866A (zh) * | 2022-03-14 | 2022-07-05 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于血液的遗忘型轻度认知损害早期诊断外周血蛋白标志物、应用及其医疗辅助诊断系统 |
| EP4549945A1 (en) * | 2022-06-28 | 2025-05-07 | Mcbi Inc. | Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device |
| WO2024195825A1 (ja) * | 2023-03-22 | 2024-09-26 | 味の素株式会社 | 血中メタボロームによる脳萎縮の評価方法 |
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025057945A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人三重大学 | 対象が脳アミロイド血管症を有するかを判定するための方法、アルツハイマー病に対する抗アミロイドβ抗体による治療の副作用のリスクまたは存在を判定するための方法、およびアルツハイマー病に対する抗アミロイドβ抗体による治療の対象を選択するための方法、ならびにそのための組成物およびキット |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| JP2005510722A (ja) * | 2001-11-23 | 2005-04-21 | シン．クス ファーマ、インコーポレイテッド | アルツハイマー病を予測するｐｅｄｆバイオポリマーマーカー |
| CA2745998C (en) | 2002-08-23 | 2013-11-26 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers for diagnosing alzheimer's disease |
| US7598049B2 (en) * | 2003-11-19 | 2009-10-06 | Satoris, Inc. | Methods for diagnosis of Alzheimer's Disease in blood samples |
| GB0421639D0 (en) * | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| DE102010026238B4 (de) * | 2010-06-29 | 2012-08-16 | Schuberth Gmbh | Schutzhelm und Tragkorb für einen Schutzhelm |
-
2013
- 2013-12-13 GB GBGB1322094.2A patent/GB201322094D0/en not_active Ceased
-
2014
- 2014-12-12 EP EP14830849.7A patent/EP3080609B1/en active Active
- 2014-12-12 US US15/104,149 patent/US12345717B2/en active Active
- 2014-12-12 CA CA2933398A patent/CA2933398C/en active Active
- 2014-12-12 JP JP2016538603A patent/JP6803230B2/ja active Active
- 2014-12-12 WO PCT/GB2014/053692 patent/WO2015087087A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500562A5 (enExample) | ||
| Choi et al. | Increased plasma levels of lipocalin 2 in mild cognitive impairment | |
| Zhang et al. | Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease | |
| Hesse et al. | Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke | |
| Teunissen et al. | Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics | |
| Roche et al. | Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers | |
| Awad et al. | Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis | |
| Zhang et al. | A comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome | |
| Hardy-Sosa et al. | Diagnostic accuracy of blood-based biomarker panels: a systematic review | |
| Nielsen et al. | Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies | |
| Shen et al. | Proteomics analysis of blood serums from Alzheimer’s disease patients using iTRAQ labeling technology | |
| JP2016533499A5 (enExample) | ||
| AU2014311258B2 (en) | Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases | |
| Popp et al. | Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer’s disease | |
| US6670137B2 (en) | Differential diagnosis of neurological diseases | |
| Bednarska-Makaruk et al. | Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia | |
| Cutler et al. | Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: two novel biomarkers of Alzheimer's disease in human plasma | |
| Akuffo et al. | The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone | |
| Sohma et al. | Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies | |
| US20110143380A1 (en) | Alzheimer's disease biomarkers and methods of use | |
| JP2018516849A5 (enExample) | ||
| Davidsson et al. | Proteome studies of CSF in AD patients | |
| Dong et al. | The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics | |
| Lleó et al. | Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders? | |
| Verpillot et al. | Analysis of amyloid-β peptides in cerebrospinal fluid samples by capillary electrophoresis coupled with LIF detection |